Emulsion formulations
US12357643B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 13, 2023 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Nov 13, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.